Endo Weightloss Maint

---
name: endo-weightloss-maint
description: This skill suggests using approved weight‑loss medication over no pharmacological therapy to ameliorate comorbidities and improve physical activity in adults with BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one comorbid condition. It is triggered when a clinician asks, for example, 'Should I add medication to help maintain weight loss in this patient with BMI 31 and diabetes?' or 'Is pharmacotherapy appropriate for long‑term weight control in a patient with BMI 28 and hypertension?'.
---

# Consider weight‑loss medication for long‑ term maintenance

## STEP 1 — Gather Information
Collect patient’s height and weight to calculate BMI, document presence of comorbid conditions (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea), review current weight‑loss efforts (diet, exercise, behavioral therapy), list current medications and any contraindications to specific weight‑loss agents (e.g., uncontrolled heart disease, pregnancy, history of serotonin‑syndrome risk).

## STEP 2 — Rule In / Rule Out
**If** BMI ≥ 30 kg/m² **OR** (BMI ≥ 27 kg/m² **AND** at least one comorbid condition) **→** proceed to Step 3.  
**Else** → weight‑loss medication not indicated; continue lifestyle‑only approach.

## STEP 3 — Classify or Stratify
Assess for medication‑specific contraindications:  
- Avoid sympathomimetics (phentermine, diethylpropion) in uncontrolled hypertension, heart disease, hyperthyroidism, glaucoma, or history of substance abuse.  
- Avoid lorcaserin if patient is on SSRIs, SNRIs, MAOIs, triptans, or dextromethorphan (serotonin‑syndrome risk).  
- Avoid orlistat in chronic malabsorption syndromes, pregnancy, or breastfeeding.  
If no contraindications → candidate for pharmacotherapy; if contraindications present → note which agents to avoid and consider alternatives.

## STEP 4 — Decide
For candidates without contraindications, initiate an approved weight‑loss medication (e.g., orlistat, lorcaserin, phentermine/topiramate, naltrexone/bupropion, liraglutide) as an adjunct to comprehensive lifestyle modification, titrate to tolerability, and schedule follow‑up assessment of efficacy and safety at least monthly for the first 3 months then every 3 months thereafter. If contraindications limit all options, emphasize intensified lifestyle intervention and reassess eligibility periodically.

## Clinical Guardrails / Mimics / Pitfalls
Do not prescribe sympathomimetic agents in patients with uncontrolled hypertension or known cardiovascular disease; avoid lorcaserin in patients on serotonergic antidepressants due to serotonin‑syndrome risk; do not use weight‑loss medication as monotherapy—must be combined with lifestyle changes; avoid orlistat in patients with chronic malabsorption or who are pregnant; discontinue medication if <5 % weight loss at 3 months or if safety/tolerability issues arise.

## Concrete Clinical Example
A 52‑year‑old woman with BMI 28 kg/m² and hypertension has tried diet and exercise for 6 months but reports weight regain. She has no contraindications to lorcaserin and is not on serotonergic antidepressants. The clinician decides to add lorcaserin 10 mg BID to her lifestyle program, schedules a follow‑up visit in 4 weeks to assess tolerability and weight change, and plans to evaluate efficacy at 3 months.

**Source:** Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2015, DOI:10.1210/jc.2014-3415